Navigation Links
Tests show bright future for gadonanotubes in stem cell tracking
Date:11/12/2010

Gadonanotubes (GNTs) developed at Rice University are beginning to show positive results in a study funded by a federal stimulus grant through the National Institutes of Health (NIH) last year.

The study has determined GNTs are effective in helping doctors track stems cells through the body by making them 40 times better than standard contrast agents used in magnetic resonance imaging. Contrast agents help doctors spot signs of disease or damage in MR images.

Researchers at Rice and the Texas Heart Institute at St. Luke's Episcopal Hospital in Houston reported in the journal Biomaterials that mesenchymal stem cells drawn from pig bone marrow labeled with GNTs are easily spotted under MRI. The technique holds promise for tracking the progress of tagged cells as they travel through a patient's body.

Ultimately, the team hopes the magnetic properties of tagged stem cells will allow doctors to manipulate them in vivo and direct cells to specific locations -- in the heart, for instance -- where they can heal damaged tissue.

GNTs are carbon nanotubes that contain gadolinium, an element commonly used in designing contrast elements for use in MRI. Though toxic, gadolinium is chelated, or chemically bound, which makes it safer for injection into the body. But clinical agents like the gadolinium-based Magnevist cannot enter cells.

However, GNTs can. Invented in the lab of Rice chemistry professor Lon Wilson in 2005, the nanotubes sequester bundles of gadolinium ions, which enhance contrast in MRIs but cannot escape their carbon cages. This makes them biologically inert and safe for tagging cells from within.

The team found GNTs did not affect the stem cells' ability to differentiate into other types of cells or to self-renew, though work continues to characterize their ability to adhere to cell scaffolds under various conditions.


'/>"/>

Contact: David Ruth
druth@rice.edu
713-348-6327
Rice University
Source:Eurekalert

Page: 1

Related biology news :

1. Built-in timer for improving accuracy of cost saving paper-strip medical tests
2. PNNL and Air Force 59th to develop better tests for drug abuse and dependence
3. Initial trials on new ovarian cancer tests exhibit extremely high accuracy
4. AMP comments at FDA meeting on array-based tests
5. Plastic antibody works in first tests in living animals
6. Pitt researcher says simple polymer-based filter successfully cleans water, recovers oil in Gulf of Mexico tests
7. New technique enables drug tests via exhaled breath
8. Microfluidic integrated circuit could help enable home diagnostic tests
9. Papaya extract thwarts growth of cancer cells in lab tests
10. AMP releases statement on oversight of laboratory tests
11. Scientists take step toward simple and portable tuberculosis tests for developing world
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2014)... Fla. , Dec. 3, 2014  Crossmatch™, ... today announced that its DigitalPersona ® Pro ... readers have been deployed throughout First Bank branch ... South Carolina and Virginia. First ... Southern Pines, North Carolina , ...
(Date:12/3/2014)... As part of our commitment to offering ... to announce the release of a new reader that ... workforce data that they need. The Atlas ... existing readers. Many such devices have serious shortcomings when ... Older models force users to navigate numerous complicated steps ...
(Date:11/21/2014)... Nov. 19, 2014  Earlier this year Donald ... College, and one of the most prolific inventors in ... are transmitted from Smartphones to third party agencies. Spector ... has one of the earliest known patents in this ... in the military, child care, elder care and hospital ...
Breaking Biology News(10 mins):First Bank Partners with Crossmatch to Increase Log In Security 2First Bank Partners with Crossmatch to Increase Log In Security 3Inception Technologies to Release New Biometric Reader 2Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 2Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 4
... Rochelle, NY, December 12, 2012ExxonMobil and many other ... dollars to develop transportation biofuels from renewable resources ... microalgae. As global supplies of fossil fuels continue ... promising source of low-cost, scalable renewable energy. The ...
... painstaking effort to create a biocompatible patch to heal infant ... Hospital. The proof is in a petri dish in ... beats with the rhythm of a living heart. Jacot, ... their tissue-engineering colleagues have published the results ofyears of effort ...
... Springer and the Italian Society for Ultrasound in Medicine and ... the Journal of Ultrasound , starting in 2013 with ... is the official journal of SIUMB. It will be available ... formerly published by Elsevier. The Journal of Ultrasound ...
Cached Biology News:Can algae-derived oils support large-scale, low-cost biofuels production? 2Rice, Texas Children's team creates biocompatible patch to heal infants with birth defects 2Rice, Texas Children's team creates biocompatible patch to heal infants with birth defects 3Springer will collaborate with the Italian Society for Ultrasound in Medicine and Biology 2
(Date:12/17/2014)... 17, 2014 CASI Pharmaceuticals, Inc. (Nasdaq: ... acquisition, development and commercialization of innovative therapeutics addressing cancer ... with a primary commercial focus on China ... a Type C meeting with the U.S. Food and ... held in February 2015.  During this meeting the Company ...
(Date:12/15/2014)... Israel , Dec. 15, 2014  BrainStorm ... leading developer of adult stem cell technologies for neurodegenerative ... Ltd. was awarded a grant of approximately $1.1 million ... Chief Scientist (OCS).  This is the eighth year that ... the Office of the Chief Scientist, which is part ...
(Date:12/15/2014)... COPENHAGEN, Denmark , Dec. 15, 2014 /PRNewswire/ ... its innovative TransCon technology to address significant unmet ... from its ongoing Phase 2 pediatric study to ... growth hormone deficiency, or GHD.  This interim analysis ... the anticipated total enrollment in the study, completing ...
(Date:12/13/2014)... (PRWEB) December 12, 2014 The ... million in 2013, and is expected to grow ... 2019. , Browse through the TOC of the ... industry trends and segments, with help of various ... The global DNA Microarray market consists of instrument, ...
Breaking Biology Technology:CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 2CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 3CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 4CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 5BrainStorm Receives $1,100,000 for its 8th Annual Non-Dilutive Grant from Israel's Chief Scientist Office 2BrainStorm Receives $1,100,000 for its 8th Annual Non-Dilutive Grant from Israel's Chief Scientist Office 3Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4DNA Microarray Market Is Expected to Grow at a CAGR of 15.2% from 2014 to 2019 - A Report by MicroMarket Monitor 2DNA Microarray Market Is Expected to Grow at a CAGR of 15.2% from 2014 to 2019 - A Report by MicroMarket Monitor 3DNA Microarray Market Is Expected to Grow at a CAGR of 15.2% from 2014 to 2019 - A Report by MicroMarket Monitor 4
... INCLINE VILLAGE, Nev., Sept. 8 PDL BioPharma, ... guidance for the third quarter ended September 30, 2009 of ... third quarter of 2008. Royalty revenues are based on second ... for Synagis(R), which is marketed by MedImmune. When compared with ...
... NOVATO, Calif., Sept. 8 BioMarin Pharmaceutical Inc. (Nasdaq: ... will present a company update at the Morgan Stanley Healthcare Conference in ... , , Interested parties may access a ... the BioMarin website, www.BMRN.com . A replay of ...
... 8 Savient Pharmaceuticals, Inc. (Nasdaq: SVNT ) announced ... failure gout will be presented at the 2009 ACR/ARHP Annual Scientific ... posters will be presented during the "Treatment and Outcome" session on ... , Chronic Use of Pegloticase: Safety ...
Cached Biology Technology:PDL BioPharma Provides Third Quarter 2009 Revenue Guidance of Approximately $71 Million 2PDL BioPharma Provides Third Quarter 2009 Revenue Guidance of Approximately $71 Million 3BioMarin to Present at the Morgan Stanley Healthcare Conference 2Multiple Abstracts Related to KRYSTEXXA(TM) Development and Treatment Failure Gout to be Presented at the 2009 ACR/ARHP Annual Scientific Meeting 2Multiple Abstracts Related to KRYSTEXXA(TM) Development and Treatment Failure Gout to be Presented at the 2009 ACR/ARHP Annual Scientific Meeting 3Multiple Abstracts Related to KRYSTEXXA(TM) Development and Treatment Failure Gout to be Presented at the 2009 ACR/ARHP Annual Scientific Meeting 4